Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial

Benzer Materyaller

• Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
  Yazar:: Chey, William D., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
  Yazar:: Chey, William D., ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
  Yazar:: Heidelbaugh, Joel J, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
  Yazar:: Eswaran, Shanti, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
  Yazar:: Rao, Satish, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)